Monopar Historical Balance Sheet
MNPR Stock | USD 19.40 0.70 3.48% |
Trend analysis of Monopar Therapeutics balance sheet accounts such as Net Tangible Assets of 10.9 M provides information on Monopar Therapeutics' total assets, liabilities, and equity, which is the actual value of Monopar Therapeutics to its prevalent stockholders. By breaking down trends over time using Monopar Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Monopar Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Monopar Therapeutics is a good buy for the upcoming year.
Monopar |
About Monopar Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Monopar Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Monopar Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Monopar Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Monopar currently owns. An asset can also be divided into two categories, current and non-current.
Monopar Therapeutics Balance Sheet Chart
Add Fundamental
Total Current Liabilities
Total Current Liabilities is an item on Monopar Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Monopar Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Accounts Payable
An accounting item on the balance sheet that represents Monopar Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Monopar Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most accounts from Monopar Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Monopar Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.At this time, Monopar Therapeutics' Other Current Assets are relatively stable compared to the past year.
2021 | 2022 | 2023 | 2024 (projected) | Total Current Liabilities | 1.6M | 3.1M | 1.8M | 1.1M | Total Assets | 20.5M | 13.2M | 7.3M | 11.5M |
Monopar Therapeutics balance sheet Correlations
Click cells to compare fundamentals
Monopar Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Monopar Therapeutics balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 13.4M | 16.9M | 20.5M | 13.2M | 7.3M | 11.5M | |
Total Current Liabilities | 724.2K | 1.2M | 1.6M | 3.1M | 1.8M | 1.1M | |
Total Stockholder Equity | 12.6M | 15.7M | 18.9M | 10.1M | 5.6M | 10.4M | |
Net Tangible Assets | 6.9M | 12.6M | 15.7M | 18.9M | 21.8M | 10.9M | |
Retained Earnings | (25.9M) | (32.2M) | (41.3M) | (51.8M) | (60.2M) | (57.2M) | |
Accounts Payable | 724.2K | 1.2M | 1.6M | 3.1M | 1.8M | 1.1M | |
Cash | 13.2M | 16.7M | 20.3M | 8.2M | 7.3M | 10.5M | |
Total Liab | 724.2K | 1.2M | 1.6M | 3.1M | 1.8M | 1.1M | |
Total Current Assets | 13.2M | 16.8M | 20.5M | 13.2M | 7.3M | 11.2M | |
Other Current Liab | 724.2K | 1.2M | 1.6M | (48.6K) | 1.8B | 1.8B | |
Net Debt | (13.2M) | (16.7M) | (20.3M) | (8.2M) | (7.3M) | (7.6M) | |
Non Current Assets Total | 0.0 | 122.4K | 68.9K | 61.2K | 12.6K | 12.0K | |
Cash And Short Term Investments | 13.2M | 16.7M | 20.3M | 13.1M | 7.3M | 12.2M | |
Common Stock Shares Outstanding | 10.6M | 11.0M | 12.5M | 12.7M | 14.5M | 12.7M | |
Liabilities And Stockholders Equity | 13.4M | 16.9M | 20.5M | 13.2M | 7.3M | 12.6M | |
Capital Surpluse | 28.0M | 28.6M | 38.5M | 47.9M | 55.1M | 32.5M | |
Other Current Assets | 5.4K | 62.7K | 217.7K | 46.0K | 66.4K | 99.5K | |
Other Stockholder Equity | 38.5M | 47.9M | 60.2M | 61.9M | 65.8M | 46.1M | |
Net Invested Capital | 12.6M | 15.7M | 18.9M | 10.1M | 5.6M | 5.3M | |
Net Working Capital | 12.5M | 15.6M | 18.9M | 10.0M | 5.6M | 5.3M | |
Common Stock | 10.6K | 11.5K | 12.6K | 12.9K | 14.9K | 12.7K | |
Accumulated Other Comprehensive Income | (11.0K) | (7.9K) | (3.2K) | 8.9K | (14.1K) | (13.4K) | |
Capital Stock | 10.6K | 11.5K | 12.6K | 12.9K | 14.9K | 13.2K |
Pair Trading with Monopar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Monopar Stock
0.86 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.82 | AGL | agilon health Buyout Trend | PairCorr |
0.81 | NKTX | Nkarta Inc | PairCorr |
0.79 | MTEM | Molecular Templates | PairCorr |
0.78 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.
The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.